Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) on Monday announced the publication of Phase 2 SARA-INT trial results for BIO101 in the Journal of Cachexia, Sarcopenia and Muscle.

The findings confirm the company's readiness to advance to Phase 3 in the development of a potential treatment for sarcopenia.

BIO101 demonstrated a clinically meaningful improvement in the 400-metre walk test, the study's primary endpoint, and showed a strong safety profile with no serious adverse events. The treatment was particularly effective in high-risk populations, including slow walkers and patients with sarcopenic obesity.

With no approved therapeutic solutions for sarcopenia, which affects up to 194 million people globally, Biophytis remains at the forefront of innovation in this field. The company is making regulatory progress for Phase 3 trials and is in active discussions with a major pharmaceutical partner in China and other industrial collaborators in Asia.